Literature DB >> 6421157

Optimal therapy for enterococcal endocarditis.

J Herzstein, J L Ryan, R J Mangi, T P Greco, V T Andriole.   

Abstract

Enterococcal endocarditis accounts for an increasing proportion of cases of endocarditis in recent years. The combination of a penicillin and an aminoglycoside has become an accepted standard of treatment for this disease. However, the optimal choice of antibiotics, duration of therapy, and timing of surgical intervention remain controversial. This study reviews the presentation, clinical course, treatment, and outcome in 37 patients with 42 separate episodes of enterococcal endocarditis at four Yale University hospitals. Patients treated with aminoglycosides and penicillins or vancomycin had significantly better outcomes than those who did not receive aminoglycosides. However, the duration of aminoglycoside therapy (more than four versus less than four weeks) did not appear to affect outcome significantly. These results suggest that excellent cure rates may be achieved after treatment for less than four weeks with an aminoglycoside in combination with penicillin or vancomycin, thus potentially avoiding significant renal and vestibular toxicity.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6421157     DOI: 10.1016/0002-9343(84)90772-1

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  16 in total

1.  Activity of LY146032 in vitro and in experimental enterococcal pyelonephritis.

Authors:  P M Miniter; T F Patterson; M A Johnson; V T Andriole
Journal:  Antimicrob Agents Chemother       Date:  1987-08       Impact factor: 5.191

2.  Bactericidal activity of deptomycin (LY146032) compared with those of ciprofloxacin, vancomycin, and ampicillin against enterococci as determined by kill-kinetic studies.

Authors:  C W Stratton; C Liu; H B Ratner; L S Weeks
Journal:  Antimicrob Agents Chemother       Date:  1987-07       Impact factor: 5.191

Review 3.  Current perspectives on glycopeptide resistance.

Authors:  N Woodford; A P Johnson; D Morrison; D C Speller
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

4.  Reply to Koehler et al.

Authors:  Maya Beganovic; Megan K Luther; Louis B Rice; Cesar A Arias; Michael J Rybak; Kerry L LaPlante
Journal:  Clin Infect Dis       Date:  2019-08-16       Impact factor: 9.079

5.  Multiply high-level-aminoglycoside-resistant enterococci isolated from patients in a university hospital.

Authors:  I Nachamkin; P Axelrod; G H Talbot; S H Fischer; C B Wennersten; R C Moellering; R R MacGregor
Journal:  J Clin Microbiol       Date:  1988-07       Impact factor: 5.948

Review 6.  Infective endocarditis during infancy and childhood: current status.

Authors:  S K Sanyal; M A Saleh; A Abu-Melha
Journal:  Indian J Pediatr       Date:  1988 Jan-Feb       Impact factor: 1.967

Review 7.  The life and times of the Enterococcus.

Authors:  B E Murray
Journal:  Clin Microbiol Rev       Date:  1990-01       Impact factor: 26.132

8.  Failure to demonstrate a consistent in vitro bactericidal effect of trimethoprim-sulfamethoxazole against enterococci.

Authors:  A Najjar; B E Murray
Journal:  Antimicrob Agents Chemother       Date:  1987-05       Impact factor: 5.191

9.  Detection of enterococcal high-level aminoglycoside resistance with MicroScan freeze-dried panels containing newly modified medium and Vitek Gram-Positive Susceptibility cards.

Authors:  D Weissmann; J Spargo; C Wennersten; M J Ferraro
Journal:  J Clin Microbiol       Date:  1991-06       Impact factor: 5.948

10.  Treatment of streptomycin-susceptible enterococcal experimental endocarditis with combinations of penicillin and low- or high-dose streptomycin.

Authors:  N K Henry; W R Wilson; J E Geraci
Journal:  Antimicrob Agents Chemother       Date:  1986-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.